Идёт набор NCT06781437

Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)

— Наблюдательное Lymphoproliferative Syndrome, Autoimmune Lymphoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально: Состояния в реестре: Lymphoproliferative Syndrome, Autoimmune, Lymphoma. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Италия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Studio Osservazionale Retrospettivo Di Coorte Italiana Di Pazienti Con Linfoma (RETRO-LYMPH)

Обзор

observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021

Подробное описание

observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021.

Study objectives are to enrich the data on the prognostic role of clinical and epidemiological factors associated with clinical and epidemiological data of patients;

* to identify the factors that affect the evolution of the disease, such as lifestyle and occupational factors, as well as the type of treatment; * to provide a platform for future research projects; * Description of the various therapies that have occurred over time, duration of treatment, causes of interruption of treatment, responses; * Description of the adverse events / safety of the various therapies for lymphoma and lymphoproliferative syndromes; * Patient survival. Descriptive analyses will be conducted by tabulating frequency distributions and percentages and mean and median values, standard deviations, quartiles and extreme values for continuous variables. Progression-free survival, disease-free survival and overall survival will be examined using Kaplan-Meier point estimates

Первичные конечные точки

Incidence and prevalence of lymphomas/lymphoproliferative syndromes referred to the Centre between January 1980 and September 2021 [Срок оценки: through study completion, an average of 6 years]

Вторичные конечные точки (12)

Overall Survival (OS) [Срок оценки: through study completion, an average of 6 years]
event free survival (EFS) [Срок оценки: through study completion, an average of 6 years]
Lymphoma specific survival (LSS) [Срок оценки: through study completion, an average of 6 years]
Progression Free Survival (PFS) [Срок оценки: through study completion, an average of 6 years]
Net survival (5 years) [Срок оценки: through study completion, an average of 6 years]
Response rate (5 years) [Срок оценки: through study completion, an average of 6 years]
Duration of Response (DoR) [Срок оценки: through study completion, an average of 6 years]
time to next anti-lymphoma treatment (TTNLT) [Срок оценки: through study completion, an average of 6 years]
Duration of survival after progression [Срок оценки: through study completion, an average of 6 years]
lymphoma transformation frequency [Срок оценки: through study completion, an average of 6 years]
Frequency of secondary neoplasy [Срок оценки: through study completion, an average of 6 years]
frequency of other chronic diseases [Срок оценки: through study completion, an average of 6 years]

Критерии участия

Критерии включения

Age greater than or equal to 18 years of enrollment
Diagnosis of lymphoma or lymphoproliferative syndrome between January 1980 and September 2021
Signature of the informed consent form where applicable